Clinical Study On195Cases Of Patients With Hypercoagulability Of Non-small Lung Cancer

Objective To discuss the blood testing laboratory and clinical characteristics ofnon-small cell lung cancer with hypercoagulability, so as to prevent thehypercoagulable state in patients with non small cell lung cancer and provides a newreference for treatment.Methods A total of195non-small cell lung cancer patients withhypercoagulability character data in Beijing Military Region Oncology from March2011and Nov2012were investigated.Age, gender, pathological type, clinical stage,operation, chemotherapy, radiotherapy, concomitant disease, body condition score andwhether the occurrence of thrombosis of patients were recorded. The hypercoagulablestate index were investigated, through the analysis of the above statistics, the bloodtesting laboratory and clinical characteristics of non-small cell lung cancer withhypercoagulability were summarized.Results Among195cases,170cases hypercoagulabe indicators are abnormal,9cases Venous thromboembolism happened, about of87.2%patients with non smallcell lung cancer were in the hypercoagulable state, The most was FIB increased in78cases (40%). Secondly, D-D increased were in60cases (30.8%), PLT elevated werein45patients (23.1%) again, PT shortened were in42cases (21.5%), APTT reducedwere in15cases (7.7%), and TT droped were in5cases (2.6%). Among them two ofthese abnormalities in62(31.8%), with FIB, DD mostly increased in32cases(16.4%); three abnormalities in27cases (13.8%), with FIB, PLT, DD mostly elevatedin15cases (7.7%).1. The relationship between hypercoagulable state indicators and clinical stage inNSCLC patients the mean FIB were significant difference between III、Ⅳ stage andⅠ-Ⅱ stage(P<0.05).2. The relationship between hypercoagulable state indicators and gender inNSCLC patients the mean TT were significant difference between male and female,the female group had lower level of TT than male group(P<0.05).3. The relationship between hypercoagulable state indicators and pathology inNSCLC patients the mean FIB were significant difference between adenocarcinoma and other pathological category (P<0.05).4. The relationship between hypercoagulable state indicators and ECOGperfomance score in NSCLC patients status ECOG>2group have higher level of FIBthan ECOG≤2groups while the level of PT seems opposite, a two-sided p value <0.05was considered statistically significant (P<0.05).5. The relationship between hypercoagulable state indicators and chemotherapyin NSCLC patients the mean PT were significant difference between chemotherapygroup and no chemotherapy group (P<0.05).6. The relationship between hypercoagulable state indicators and merger disease inNSCLC patients the the mean FIB were significant difference between merger diseasegroup and single non-small lung cancer group (P<0.05).7. The relationship between hypercoagulable state indicators and central venouscatheters in NSCLC patients there were insignificant difference between the group ofCVCS ang the group of no CVCS(P<0.05).8. The group of NSCLC thrombosis incidence rate was4.6%. Thrombotic groupcompared with non-thrombotic group, the ages older than60、ECOG score higer than2and merger disease had significant difference (P<0.05).Conclusions Non-small cell lung cancer prevalence hypercoagulable state,coagulation abnormalities detected with FIB, DD, PLT increased majority, the clinicalrisk factors for female, cancer, TNM stage late, receiving chemotherapy andassociated comorbidities, clinical need for patients with different clinicalcharacteristics and laboratory indicators, develop appropriate anticoagulation therapyprograms to improve the quality of life of patients and improve prognosis.